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Statin Therapy Alters the Relationship
Between Apolipoprotein B and Low-Density
Lipoprotein Cholesterol and Non–High-Density
Lipoprotein Cholesterol Targets in High-Risk Patients
The MERCURY II (Measuring Effective
Reductions in Cholesterol Using Rosuvastatin therapY II) Trial
Christie M. Ballantyne, MD, FACC,* Joel S. Raichlen, MD, FACC,† Valerie A. Cain, MS†
Houston, Texas; and Wilmington, Delaware
Objectives The purpose of this analysis was to compare concentrations of low-density lipoprotein cholesterol (LDL-C), non–
high-density lipoprotein cholesterol (HDL-C), and apolipoprotein B (apoB) before and during statin therapy.
Background Reducing LDL-C to a pre-determined goal may still leave an excess of atherogenic lipoproteins, as reflected in
apoB levels.
Methods The MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY II) trial examined
the effects of statin treatment in patients with high coronary heart disease (CHD) risk, LDL-C 130 and 250
mg/dl, and triglycerides 400 mg/dl. Therapy consisted of rosuvastatin (10 or 20 mg), atorvastatin (10 or 20
mg), or simvastatin (20 or 40 mg). The apoB and LDL-C or non–HDL-C at baseline and after 16 weeks of therapy
were compared using linear regression.
Results In untreated patients, the apoB target of 90 mg/dl was roughly equivalent to an LDL-C level 100 mg/dl and
a non–HDL-C level 130 mg/dl, which is consistent with existing apoB and lipoprotein guidelines. However, dur-
ing statin therapy, to reach an apoB target of 90 mg/dl it was necessary to reduce non–HDL-C to 100 mg/dl
or to reduce LDL-C to 70 mg/dl (in high-triglyceride patients) or 80 mg/dl (in lower-triglyceride patients). The
tight correlation seen for non–HDL-C with apoB while on statin therapy (R2  0.92) implies that non–HDL-C may
be an acceptable surrogate for direct apoB measurement.
Conclusions These data are consistent with the more aggressive cholesterol goals suggested for CHD patients, because
achieving such targets also reduced apoB to the recommended level. (Mercury II–Compare the Efficacy and
Safety of Lipid Lowering Agents Atorvastatin and Simvastatin With Rosuvastatin in High Risk Subjects With Type
IIa and IIb Hypercholesterolemia; NCT00654407) (J Am Coll Cardiol 2008;52:626–32) © 2008 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.04.052a
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cirtually all cholesterol in the blood is carried in lipoprotein
articles. Although the National Cholesterol Education
rogram Adult Treatment Panel III (ATP III) guidelines
ocus on low-density lipoprotein cholesterol (LDL-C)
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008, accepted April 29, 2008.s the primary target of therapy unless triglyceride (TG)
evels are severely elevated (1), other lipoproteins, such as
ntermediate-density lipoprotein, very-low-density lipopro-
ein remnants, and lipoprotein(a), may also be atherogenic.
atients, particularly those with high baseline TG concen-
rations, may still carry an excess of atherogenic particles
See page 633
espite lowering LDL-C to recommended goals (2–12).
or these reasons, in patients with elevated TG (200 mg/dl),
on–high-density lipoprotein cholesterol (HDL-C) con-
entration, which reflects the cholesterol carried by all
therogenic particles, is recommended as a secondary target
o
p
n
v
f
i
t
w
l
t
E
a
a
l
f

g
w
A
C
t
H
m
i
w
I
o
i
F
p
t
l
L
t
t
l
a
M
F
r
o
l
a
v
w
o
r
d
o
I

l
r
a
l
a
R
H
L
F
t

L
q
i
t
L
h
f
1
i
g
m
n
a
m
m
l
m
f
a
a
a
d
v
p
v
T
T
a
v
w
Do
A
r
627JACC Vol. 52, No. 8, 2008 Ballantyne et al.
August 19, 2008:626–32 Statins Alter Relation of ApoB, LDL-C, and Non–HDL-Cf therapy. An alternative approach is to measure apoli-
oprotein B (apoB) concentration, which measures the total
umber of atherogenic particles in blood (2). The predictive
alue of apoB as the strongest single lipid-associated risk
actor has been shown in large observational studies (13,14),
n primary prevention trials (15), and in secondary preven-
ion trials (16). The lowest values of apoB were associated
ith the lowest cardiovascular event rates. A “desirable”
evel of apoB of 88 mg/dl was estimated from the distribu-
ion of apoB levels in the National Health and Nutrition
xamination Survey III data (17). Those data show that this
pproximate level (88 mg/dl) is found in younger age groups
nd in those with lower LDL-C values. Similarly, a target
evel of apoB 90 mg/dl has been proposed by Grundy (7)
or high-risk patients in addition to the target of LDL-C
100 mg/dl (and non–HDL-C 130 mg/dl for hypertri-
lyceridemic patients), and more recently the same targets
ere recommended in a consensus statement from the
merican Diabetes Association (ADA) and the American
ollege of Cardiology (ACC) Foundation to guide the
herapy of patients with high cardiometabolic risk (18).
owever, the target numbers suggested in those guidelines
ay not accurately account for treatment-induced changes
n lipid and lipoprotein parameters observed with statins,
hich are recommended as first-line treatment in the ATP
II guidelines.
High-risk patients frequently have higher baseline levels
f apoB than predicted by the level of LDL-C because of
ncreased concentration of small dense LDL particles.
urthermore, statin therapy reduces LDL-C by a greater
ercentage than it does apoB (19). Therefore, we examined
he relationship between apoB, LDL-C, and non–HDL-C
evels and, most importantly for clinicians, what levels of
DL-C and non–HDL-C on statin therapy are equivalent to
he suggested apoB target level of 90 mg/dl, using data from
he MERCURY II (Measuring Effective Reductions in Cho-
esterol Using Rosuvastatin therapY II) trial, which enrolled
lmost 2,000 high-risk patients with hyperlipidemia (20).
ethods
ull details of the methods of the MERCURY II trial are
eported elsewhere (20). In this multicenter, international,
pen-label trial, 1,993 high-risk patients requiring lipid-
owering therapy underwent a 6-week dietary lead-in phase
nd were randomized to receive rosuvastatin 20 mg, ator-
astatin 10 or 20 mg, or simvastatin 20 or 40 mg for 8
eeks, after which they either remained on initial treatment
r were switched to mg-equivalent or lower doses of
osuvastatin for an additional 8 weeks. Patients had a
ocumented history of coronary heart disease (CHD) or
ther established atherosclerotic disease, diabetes, or ATP
II 10-year risk of CHD 20% (1) and had fasting LDL-C
130 and 250 mg/dl and TG 400 mg/dl. Baseline lipid
evels were the average of 2 measurements before the start of
andomized treatment; lipids were measured again after 8
And 16 weeks of therapy. All
aboratory samples were analyzed
t a central laboratory (Medical
esearch Laboratories, Highland
eights, Kentucky). The level of
DL-C was calculated by the
riedewald equation except for
hose visits at which TG was
400 mg/dl, when the level of
DL-C was measured by beta-
uantification. Efficacy measures
ncluded the proportions of pa-
ients meeting the ATP III
DL-C goal of 100 mg/dl for
igh-risk patients and changes
rom baseline in lipids at 8 and
6 weeks. Supplemental analyses
ncluded proportions of hypertri-
lyceridemic patients, defined as those with TG levels200
g/dl at baseline, who met both the LDL-C target and the
on–HDL-C target (130 mg/dl) (1) and the proposed
poB target of 90 mg/dl (7) and proportions of patients
eeting the optional very-high-risk LDL-C target of 70
g/dl (21). Very-high-risk patients were those with estab-
ished cardiovascular disease and 1 of the following:
ultiple major risk factors, severe and poorly controlled risk
actors, or multiple risk factors of the metabolic syndrome.
The present analysis assessed the relationship between
poB and LDL-C or non–HDL-C levels at baseline and
fter 16 weeks of treatment with the study statins. Goal
ttainment analysis was applied to all patients with 16-week
ata. Linear regression analyses were performed for LDL-C
ersus apoB levels and non–HDL-C versus apoB levels of
ooled data for all patients with available data for those
ariables, for those with baseline TG 200 mg/dl (high
G), and for those with baseline TG 200 mg/dl (lower
G, i.e., normal or borderline-high). For the regression
nalyses, only patients with paired baseline and 16-week
alues for LDL-C and apoB or non–HDL-C and apoB
ere included.
emographic Characteristicsf Randomized Population
Table 1 Demographic Characteristicsof Randomized Population
Characteristic, n (%) Unless Noted
Randomized Population
(n  1,993)
Male gender 1,112 (55.8%)
Age, yrs, mean (SD) 61.9 (10.4)
Weight, kg, mean (SD) 87.4 (19.8)
Body mass index, kg/m2, mean (SD) 30.64 (6.1)
History of atherosclerosis 1,235 (62.0%)
Diabetes 900 (45.2%)
TG 200 mg/dl 725 (36.4%)
ll patients were “high CHD event risk” because of 1 of 3 qualifications: overt CHD, CHD
isk-equivalent disease (e.g., diabetes, atherosclerosis), or calculated 10-year CHD risk 20%.
Abbreviations
and Acronyms
ACC  American College of
Cardiology
ADA  American Diabetes
Association
AHA  American Heart
Association
apoB  apolipoprotein B
CHD  coronary heart
disease
HDL-C  high-density
lipoprotein cholesterol
LDL-C  low-density
lipoprotein cholesterol
TG  triglyceridedapted from Ballantyne et al. (20).
CHD  coronary heart disease; TG  triglycerides.
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ull results of the MERCURY II trial are reported else-
here (20); demographic characteristics are summarized in
able 1. At 16 weeks, patients switching from atorvastatin
0 and 20 mg to rosuvastatin 10 and 20 mg, respectively, or
rom simvastatin 20 and 40 mg to rosuvastatin 10 and 20
g, respectively, had significantly greater reductions in
DL-C than those remaining on initial treatment. At the
nd of the trial, 1,802 patients had both apoB and lipid data:
,082 of this total were being treated with rosuvastatin, 357
ith atorvastatin, and 363 with simvastatin.
At 16 weeks, overall least-squares mean reductions in
DL-C ranged from 32.1% to 53.7%, least-squares mean
eductions in non–HDL-C ranged from 28.7% to 48.6%,
nd least-squares mean reductions in apoB ranged from
5.0% to 42.6% (20). To produce robust correlation analy-
es, data from all treatment arms were pooled, providing a
arge dataset with a wide range of lipid and apoB levels.
The overall distributions of LDL-C and apoB were
lotted in Figure 1 for all patients who had paired data at
oth baseline and end of treatment (n  1,783). Similarly,
he distributions of non–HDL-C and apoB were plotted in
igure 2 for all patients who had paired data at both baseline
nd end of treatment (n  1,784). For the analyses shown
n Tables 2 and 3, these data were also stratified into
atients with high TG (baseline TG200 mg/dl; n 656)
nd patients with lower TG (baseline TG200 mg/dl; n
,127 for LDL-C; n  1,128 for non–HDL-C).
poB and LDL-C. The concentrations of LDL-C and
poB were well fitted by a linear regression model both at
aseline and during statin therapy (Table 2, Fig. 1). Overall,
t baseline, an apoB of 90 mg/dl corresponded to an
DL-C of 112.8 mg/dl (Table 2, Fig. 1A). Thus, in
ntreated patients at baseline, LDL-C values appeared to
orrespond to apoB values that were consistent with targets
uggested by Grundy in 2002 (7) and in the ADA/ACC
onsensus statement (18). For this analysis, patients were
ivided by baseline TG values into high TG (200 mg/dl)
nd lower TG (200 mg/dl) groups. The linear regression
odels of each group were close in slope but offset in
ntercept. Before treatment, an apoB of 90 mg/dl corre-
ponded to an LDL-C of 93.3 mg/dl in the high-TG
ubgroup and to 110.5 mg/dl in the lower-TG subgroup
Table 2).
However, statin therapy altered the relationship between
poB and LDL-C, causing the linear regression lines to
hift. Similar results were seen for each treatment arm, for
eaker as well as for stronger statins. The overall pooled
egression is shown in Table 2. For patients with high
aseline TG levels, an apoB of 90 mg/dl on statin therapy
orresponded to an LDL-C of 71.0 mg/dl (22.3 mg/dl
ower than at baseline). This corresponds to the LDL-C
arget of 70 mg/dl recommended as “optional” for very-
igh-risk patients in the ATP III update (21) and as
reasonable” for all patients with CHD or other atheroscle- rotic vascular disease in the ACC/American Heart Associ-
tion (AHA) guidelines for secondary prevention (22). For
atients with lower baseline TG levels, an apoB of 90 mg/dl
n statin therapy corresponded to an LDL-C of 82.5 mg/dl
28.0 mg/dl lower than at baseline). No differences were
ound when analyzing the relationship between LDL-C and
poB in subgroups based on gender or diabetic status. In
tatin-treated patients, the scatter of the apoB versus
DL-C data points was reduced (Fig. 1B), leading to
igher correlation coefficients, and the slopes of the linear
Figure 1 Patterns of ApoB Versus LDL-C Among
All Patients Before and After Statin Therapy
(A) All patients untreated (baseline). (B) All patients on statin therapy. Hori-
zontal lines show the upper threshold of the LDL-C goal of 100 mg/dl, and
vertical lines show the upper threshold of the proposed secondary apoB goal
of 90 mg/dl. Colors of data points denote treatment during the final 8
weeks of the trial of each patient. ApoB  apolipoprotein B; ATV  atorvasta-
tin; LDL-C  low-density lipoprotein cholesterol; RSV  rosuvastatin; SMV 
simvastatin.egression lines became steeper (Table 2).
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August 19, 2008:626–32 Statins Alter Relation of ApoB, LDL-C, and Non–HDL-CpoB and non–HDL-C. The concentrations of non–
DL-C and apoB for all patients as a group were well fitted
y a linear regression model both at baseline and during
tatin therapy (Table 3, Fig. 2). When patients were
eparated into high baseline TG and lower baseline TG
ubgroups, the linear regression lines were similar, although
he baseline data points for the high-TG patients were
lustered at higher values of apoB and non–HDL-C com-
ared with the lower-TG patients. At baseline, an apoB of
0 mg/dl corresponded to a non–HDL-C of 129.8 mg/dl
Figure 2 Patterns of ApoB Versus Non–HDL-C Among
All Patients Before and After Statin Therapy
(A) All patients untreated (baseline). (B) All patients on statin therapy. Hori-
zontal lines show the upper threshold of the non–HDL-C goal of 130 mg/dl,
and vertical lines show the upper threshold of the proposed secondary apoB
goal of 90 mg/dl. Colors of data points denote treatment during the final 8
weeks of the trial of each patient. HDL-C  high-density lipoprotein cholesterol;
other abbreviations as in Figure 1.Table 3, Fig. 2A). Thus, in untreated patients at baseline, Hon–HDL-C values appeared to correspond to apoB values
onsistent with the non–HDL-C target level of 130
g/dl suggested by Grundy in 2002 (7). The linear regres-
ion lines of the apoB and non–HDL-C values in untreated
atients with high TG and lower TG had similar slopes
Table 3).
However, as seen with the LDL-C relationship, statin
herapy altered the relationship between apoB and non–
DL-C, shifting the linear regression lines (Table 3, Fig.
B). Although mean non–HDL-C reductions among statin
reatment arms varied widely (ranging from 29% to
49%), the separate apoB versus non–HDL-C regression
ines among these treatment groups were similar. Therefore,
e were able to use a single regression line to describe the
ooled data. For patients with high baseline TG levels, an
poB of 90 mg/dl on statin therapy corresponded to a
on–HDL-C of 104.1 mg/dl (31.7 mg/dl lower than at
aseline). For patients with lower baseline TG levels, an
poB of 90 mg/dl on statin therapy corresponded to a
on–HDL-C of 104.6 mg/dl (26.1 mg/dl lower than at
aseline). These values are close to the target non–HDL-C
alue recommended as “optional” for very-high-risk patients
n the ATP III update (21) and as “reasonable” for all
atients with CHD or other atherosclerotic vascular disease
n the ACC/AHA guidelines for secondary prevention (22).
o differences were found when analyzing the relationship
etween non–HDL-C and apoB in subgroups based on
ender or diabetic status. Statin treatment reduced the
inear Regression of ApoB Versus LDL-Ct B seline (Untreated) and on Statin Therapy
Table 2 Linear Regression of ApoB Versus LDL-Cat Baseline (Untreated) and on Statin Therapy
Slope Intercept R2
LDL-C
(ApoB  90), mg/dl
Baseline
Lower TG 0.89 30.0 0.67 110.5
High TG 0.92 10.4 0.66 93.3
All patients 0.79 42.1 0.61 112.8
On statin
Lower TG 1.11 17.6 0.85 82.5
High TG 1.03 21.2 0.83 71.0
All patients 1.01 12.3 0.79 79.0
poB  apolipoprotein B; LDL-C  low-density lipoprotein cholesterol; TG  triglycerides.
inear Regression of ApoB Versus Non–HDL-Ct B seline (Untreated) and on Statin Therapy
Table 3 Linear Regression of ApoB Versus Non–HDL-Cat Baseline (Untreated) and on Statin Therapy
Slope Intercept R2
Non–HDL-C
(ApoB  90), mg/dl
Baseline
Lower TG 1.02 38.8 0.76 130.7
High TG 1.02 44.1 0.71 135.8
All patients 1.06 34.4 0.79 129.8
On statin
Lower TG 1.27 10.0 0.92 104.6
High TG 1.25 8.3 0.92 104.1
All patients 1.26 8.9 0.92 104.4DL-C  high-density lipoprotein cholesterol; other abbreviations as in Table 2.
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Statins Alter Relation of ApoB, LDL-C, and Non–HDL-C August 19, 2008:626–32catter of apoB versus non–HDL-C data points (Fig. 2B),
eading to an even higher R2 value of 0.92. On statin
reatment, the slopes of the linear regression lines became
teeper (Table 3).
uccess in meeting dual cholesterol and apoB targets.
ables 4 and 5 show the likelihood of success in reaching a
holesterol or an apoB target when the other target is first met.
ooking at each target separately, Table 4 shows that about
wo-thirds of statin-treated patients in the MERCURY II
rial met high-risk lipid targets (non–HDL-C 130 mg/dl
r LDL-C 100 mg/dl). Lipid-lowering success ranged
rom 28% for patients treated with simvastatin 20 mg to
0% for patients treated with rosuvastatin 20 mg. However,
f those meeting either the LDL-C target or the non–
DL-C target, overall only one-half succeeded in also
eaching apoB 90 mg/dl. Applying the optional lipid
argets for very-high-risk patients vastly decreased the
verall proportion of success to 21% for LDL-C70 mg/dl
nd 29% for non–HDL-C 100 mg/dl. However, of those
ho met those optional lipid targets, 86% and 92%, respec-
ively, also met the target of apoB 90 mg/dl.
A converse question can also be asked: Of those who
each the apoB target of 90 mg/dl, what proportion
eaches the lipid targets? Table 5 shows that overall, 32% of
tatin-treated patients reached apoB 90 mg/dl, ranging
rom 10% of patients treated with simvastatin 20 mg to 47%
f patients treated with rosuvastatin 20 mg. In addition, the
Percentages of Patients After 16 Weeks of StatinLDL-C or Non–HDL-C Target Who Also Reached
Table 4 Percentages of Patients After 16 WeLDL-C or Non–HDL-C Target Who A
Target Group
LDL-C 100 mg/dl Lower TG
High TG
All patients
LDL-C 70 mg/dl Lower TG
High TG
All patients
Non–HDL-C 130 mg/dl Lower TG
High TG
All patients
Non–HDL-C 100 mg/dl Lower TG
High TG
All patients
Abbreviations as in Tables 2 and 3.
ercentages of Patients After 16 Weeks of Statin Therapy atpoB <90 mg/dl Who Also Reached LDL-C or Non–HDL-C Targets
Table 5 Percentages of Patients After 16 Weeks of Statin TheApoB <90 mg/dl Who Also Reached LDL-C or Non–HD
Group
ApoB
<90 mg/dl
LDL-C
<100 mg/dl
Lower TG 39% (445/1,138*) 99% (441/445)
High TG 19% (129/664) 100% (129/129)
All patients 32% (574/1,802†) 99% (570/574)n  1,137 for LDL-C; †n  1,801 for LDL-C.
Abbreviations as in Tables 2 and 3.igh-TG group showed only a 19% overall success at
eaching the apoB goal. However, virtually all of the
atients who reached the apoB target also met the individ-
al high-risk lipid targets of LDL-C 100 mg/dl (99%)
nd non–HDL-C 130 mg/dl (99.8%). Examination of
he optional lipid targets for very-high-risk patients indi-
ated that of those who met the apoB target (apoB 90
g/dl), 58% achieved LDL-C 70 mg/dl and 82%
chieved non–HDL-C 100 mg/dl (Table 5).
iscussion
hese analyses from the MERCURY II trial show linear
orrelations between LDL-C and apoB and between non–
DL-C and apoB both before and during statin cholesterol-
owering therapy in high-risk patients. Earlier studies noted
inear correlations of LDL-C and non–HDL-C with apoB
n untreated patients and found that the correlations were
ffected by TG levels (12,19). In ACCESS (Atorvastatin
omparative Cholesterol Efficacy and Safety Study), statin
reatment was shown to affect the strength of those corre-
ations and to reduce LDL-C by a greater percentage than
t did apoB (19).
The data from high-risk patients in the MERCURY II
rial indicate that to drive the atherogenic particle concen-
ration down to the suggested apoB target value of 90
g/dl, it is necessary for statin therapy to achieve a
apy at anB <90 mg/dl
f Statin Therapy at an
eached ApoB <90 mg/dl
nts Reaching
Target
Patients Reaching Target With
ApoB <90 mg/dl
765/1,137) 58% (441/765)
423/664) 30% (129/423)
1,188/1,801) 48% (570/1,188)
242/1,137) 95% (230/242)
145/664) 71% (103/145)
387/1,801) 86% (333/387)
829/1,138) 54% (444/829)
350/664) 37% (129/350)
1,179/1,802) 49% (573/1,179)
403/1,138) 92% (372/403)
111/664) 91% (101/111)
514/1,802) 92% (473/514)
at
argets
Patients With ApoB <90 mg/dl Who Have . . .
LDL-C
<70 mg/dl
Non–HDL-C
<130 mg/dl
Non–HDL-C
<100 mg/dl
52% (230/445) 99.8% (444/445) 84% (372/445)
80% (103/129) 100% (129/129) 78% (101/129)
58% (333/574) 99.8% (573/574) 82% (473/574)TherApo
eks o
lso R
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August 19, 2008:626–32 Statins Alter Relation of ApoB, LDL-C, and Non–HDL-Cholesterol level considerably lower than expected according
o existing recommendations (7,18). These findings are
elevant because the data used to develop existing goals for
poB were from untreated subjects. Therefore, the data
resented in this analysis of patients on statin therapy have
mplications for guidelines that recommend treatment goals
or apoB, non–HDL-C, and LDL-C, because statins are
ecommended as first-line therapy in high-risk patients.
his analysis suggests that to reach an apoB level of 90
g/dl, one would need to set a target LDL-C of 70 to 80
g/dl, rather than 100 mg/dl, and a target non–HDL-C
f 100 mg/dl, rather than 130 mg/dl. These lipid values
re close to the lipid targets recommended as “optional” for
ery-high-risk patients in the ATP III update (21) and as
reasonable” for all patients with CHD or other atheroscle-
otic vascular disease in the ACC/AHA guidelines for
econdary prevention (22). Furthermore, the target of non–
DL-C 100 mg/dl works equally well for patients who
ave high baseline TG and those with lower baseline TG.
herefore, to simplify therapeutic goals, it may be appro-
riate to consider a non–HDL-C target of 100 mg/dl for
ll high-risk patients.
The atherogenic lipoprotein paradigm suggests that the
otal number of atherogenic particles is a more important
eterminant of cardiovascular risk than conventional lipid
easures such as LDL-C levels (2). One molecule of apoB
s present in each atherogenic particle of LDL, very-low-
ensity lipoprotein, intermediate-density lipoprotein, large
uoyant LDL, small dense LDL, and lipoprotein(a). There-
ore, measures of apoB provide an estimate of the total
umber of potentially atherogenic particles (10). An apoB
evel 90 mg/dl has been suggested as an optional thera-
eutic target in patients with very high risk (21), and others
ave suggested that a more aggressive target level of 80
g/dl may be considered (10). The recent ADA/ACC
onsensus statement suggested LDL-C 70 mg/dl, non–
DL-C 100 mg/dl, and apoB 80 mg/dl for patients
ith highest risk (18).
Statins directly inhibit the rate-limiting step for choles-
erol synthesis in the liver and thus stimulate expression of
epatic LDL receptors (23). Statins lower LDL-C, very-
ow-density lipoprotein cholesterol, and TG, but the reduc-
ion in LDL-C is greater than the reductions in TG and
poB (20). Therefore, on therapy, the level of apoB may not
e reduced as much as expected by the reduction of LDL-C
evels. Thus, after treatment, many individuals with LDL-C
100 mg/dl continue to have apoB 90 mg/dl. For
xample, in the trial analyzed here, of overall patients who
ad elevated TG before treatment, only 64% achieved
DL-C 100 mg/dl and only 30% of individuals with
DL-C 100 mg/dl also achieved an apoB 90 mg/dl
Table 4).
One management option for the high-risk patient is to
easure apoB during statin therapy to make sure that the
otal number of atherogenic particles is reduced. Another
ore practical approach, which would not entail any addi-ional cost, is to measure non–HDL-C, which has a good
orrelation with apoB at baseline and particularly on statin
herapy (R2  0.92). Unfortunately, the clinician must still
alculate non–HDL-C (non–HDL-C  total cholesterol 
DL-C), because it is not routinely reported by major
linical laboratories, and therefore, non–HDL-C is not
outinely used in daily clinical practice. Requiring laborato-
ies to calculate and report non–HDL-C as part of a
tandard lipid profile, just as LDL-C is already calculated
nd reported, would conveniently provide important infor-
ation on this treatment target.
onclusions
n summary, in untreated high-risk patients, we found that
n apoB level of 90 mg/dl was approximately equivalent to
n LDL-C level of 100 mg/dl and a non–HDL-C level of
30 mg/dl, which is consistent with the numbers suggested
y Grundy (7) and the ADA/ACC consensus statement
18). However, to achieve apoB 90 mg/dl on statin
herapy, it was necessary for patients to achieve LDL-C
70 (with high baseline TG) or 80 mg/dl (with lower
aseline TG) or non–HDL-C 100 mg/dl. These findings
rovide additional support for the ACC/AHA guidelines
or secondary prevention, which suggest that LDL-C 70
g/dl and non–HDL-C 100 mg/dl are reasonable targets
n all patients with CHD or other atherosclerotic vascular
isease, because achieving these targets also reduced apoB to
he recommended level.
cknowledgments
he authors thank Michael Theisen, PhD, of Scientific
onnexions, Newtown, Pennsylvania (supported by Astra-
eneca), and Kerrie Jara of Baylor College of Medicine for
ditorial assistance.
eprint requests and correspondence: Dr. Christie M. Ballan-
yne, 6565 Fannin Street, MS A601, Suite A656, Houston, Texas
7030. E-mail: cmb@bcm.edu.
EFERENCES
1. National Cholesterol Education Program (NCEP) Expert Panel on
Detection, Evaluation, and Treatment of High Blood Cholesterol in
Adults (Adult Treatment Panel III). Third report of the National
Cholesterol Education Program (NCEP) Expert Panel on Detection,
Evaluation, and Treatment of High Blood Cholesterol in Adults
(Adult Treatment Panel III): final report. Circulation 2002;106:
3143–421.
2. Barter PJ, Ballantyne CM, Carmena R, et al. Apo B versus cholesterol
in estimating cardiovascular risk and in guiding therapy: report of the
thirty-person/ten-country panel. J Intern Med 2006;259:247–58.
3. Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-I: risk
indicators of coronary heart disease and targets for lipid-modifying
therapy. J Intern Med 2004;255:188–205.
4. Lamarche B, Moorjani S, Lupien PJ, et al. Apolipoprotein A-I and B
levels and the risk of ischemic heart disease during a five-year
follow-up of men in the Quebec Cardiovascular Study. Circulation
1996;94:273–8.5. Westerveld HT, Roeters van Lennep JE, Roeters van Lennep HWO,
et al. Apolipoprotein B and coronary artery disease in women. A
11
1
1
1
1
1
1
1
1
2
2
2
2
K
632 Ballantyne et al. JACC Vol. 52, No. 8, 2008
Statins Alter Relation of ApoB, LDL-C, and Non–HDL-C August 19, 2008:626–32cross-sectional study in women undergoing their first coronary
angiography. Arterioscler Thromb Vasc Biol 1998;18:1101–7.
6. Durrington PN. Can measurement of apolipoprotein B replace the
lipid profile in the follow-up of patients with lipoprotein disorders?
Clin Chem 2002;48:401–2.
7. Grundy SM. Low-density lipoprotein, non-high-density lipoprotein,
and apolipoprotein B as targets of lipid-lowering therapy. Circulation
2002;106:2526–9.
8. Miremadi S, Sniderman A, Frohlich J. Can measurement of serum
apolipoprotein B replace the lipid profile monitoring of patients with
lipoprotein disorders? Clin Chem 2002;48:484–8.
9. Hirsch GA, Blumenthal RS. Usefulness of non-high-density lipopro-
tein cholesterol determinations in the diagnosis and treatment of
dyslipidemia. Am J Cardiol 2003;91:827–30.
0. Sniderman AD, Furberg CD, Keech A, et al. Apolipoproteins versus
lipids as indices of coronary risk and as targets for statin treatment.
Lancet 2003;361:777–80.
1. Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB.
Non-high-density lipoprotein cholesterol and apolipoprotein B in the
prediction of coronary heart disease in men. Circulation 2005;112:
3375–83.
2. Leroux G, Lemieux I, Lamarche B, et al. Influence of triglyceride
concentration on the relationship between lipoprotein cholesterol and
apolipoprotein B and A-I levels. Metabolism 2000;49:53–61.
3. Walldius G, Jungner I, Holme I, et al. High apolipoprotein B, low
apolipoprotein A-I, and improvement in the prediction of fatal
myocardial infarction (AMORIS study): a prospective study. Lancet
2001;358:2026–33.
4. Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non-HDL
cholesterol, apolipoproteins A-I and B100, standard lipid measures,
lipid ratios, and CRP as risk factors for cardiovascular disease in
women. JAMA 2005;294:326–33.
5. Gotto AM Jr., Whitney E, Stein EA, et al. Relation between baseline
and on-treatment lipid parameters and first acute major coronary
events in the Air Force/Texas Coronary Atherosclerosis Prevention
Study (AFCAPS/TexCAPS). Circulation 2000;101:477–84. n6. Simes RJ, Marschner IC, Hunt D, et al. LIPID Study Investigators.
Relationship between lipid levels and clinical outcomes in the Long-
Term Intervention With Pravastatin in Ischemic Disease (LIPID)
trial. Circulation 2002;105:1162–9.
7. Bachorik PS, Lovejoy KL, Carroll MD, Johnson CL. Apolipoprotein
B and AI distributions in the United States, 1988–1991: results of the
National Health and Nutrition Examination Survey III (NHANES
III). Clin Chem 1997;43:2364–78.
8. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management
in patients with cardiometabolic risk: consensus conference report from
the American Diabetes Association and the American College of Cardi-
ology Foundation. J Am Coll Cardiol 2008;51:1512–24.
9. Ballantyne CM, Andrews TC, Hsia JA, Kramer JH, Shear C,
ACCESS Study Group. Atorvastatin Comparative Cholesterol
Efficacy and Safety Study. Correlation of non-high-density li-
poprotein cholesterol with apolipoprotein B: effect of 5 hydroxy-
methylglutaryl coenzyme A reductase inhibitors on non-high-
density lipoprotein cholesterol levels. Am J Cardiol 2001;88:265–9.
0. Ballantyne CM, Bertolami M, Garcia HRH, et al. Achieving LDL
cholesterol, non-HDL cholesterol, and apolipoprotein B target levels
in high-risk patients: MERCURY II. Am Heart J 2006;151:
975.e1– e9.
1. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent
clinical trials for the National Cholesterol Education Program Adult
Treatment Panel III guidelines. Circulation 2004;110:227–39.
2. Smith SC Jr, Allen J, Blair SN, et al. AHA/ACC guidelines for
secondary prevention for patients with coronary and other atheroscle-
rotic vascular disease: 2006 update. J Am Coll Cardiol 2006;47:
2130–9.
3. Vaughan CJ, Gotto AM. Update on statins: 2003. Circulation
2004;110:886–92.
ey Words: apolipoprotein B y low-density lipoprotein cholesterol y
on–high-density lipoprotein cholesterol y statins y high-risk patients.
